Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06329570 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06329570 · ClinicalTrials.gov record · last posted 2026-04-09

Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

StatusRecruiting
PhasePhase 1/2
Started2024-10-22
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This will be a prospective, open-label, single-arm pilot study to investigate the safety and efficacy of Bevacizumab (BEV) in combination with microbubble (MB)-mediated FUS in patients with recurrent GBM. BEV represents the physician's best choice for the standard of care (SoC) in rGBM after previous treatment with surgery (if appropriate), standard radiotherapy with temozolomide chemotherapy, and with adjuvant temozolomide.

Amendment record 1 amendment on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended once since 2024-03-19. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2026-04-06
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT06329570
Lead Sponsor NaviFUS Corporation
Collaborators: NaviFUS US LLC
Conditions Glioblastoma Multiforme, Glioblastoma, Glioma, Brain Tumor, Neoplasms, Neoplasms, Nerve Tissue
Enrollment 10 participants
Start Date 2024-10-22
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-09